Abstract
Abstract
The aim of this study was to compare the expression of PD-1/PD-L1 in primary breast tumours to that in metastatic axillary lymph nodes and to determine the correlation between the PD-1/PD-L1 status and clinicopathologic characteristics. In total, 47 paired breast tumour and metastatic axillary lymph node samples were collected in this study. Immunohistochemical technology was used to determine the positivity or negativity of PD-1/PD-L1. Other patient information was retrieved from medical records. Significant differences in PD-L1 expression were observed between primary breast tumours and paired axillary lymph nodes. We also observed that the presence of PD-1/PD-L1 positivity in metastatic lymph nodes was significantly associated with poor prognostic features, such as a high Ki-67 index (p = 0.048), a high TNM stage (p = 0.012), a large number of metastatic lymph nodes (p = 0.002), and a high histology grade (p = 0.029). Since heterogeneity exists, it is necessary to determine the PD-L1 status in both the primary tumour and metastatic lymph nodes.
Publisher
Springer Science and Business Media LLC
Reference33 articles.
1. Ghoncheh, M., Pournamdar, Z. & Salehiniya, H. Incidence and mortality and epidemiology of breast cancer in the world. Asian Pacific journal of cancer prevention. APJCP. 17, 43–46 (2016).
2. Nagini, S. Breast Cancer: Current Molecular Therapeutic Targets and New Players. Anti-Cancer Agents in Medicinal Chemistry (2017).
3. Bonotto, M. et al. Measures of Outcome in Metastatic Breast Cancer: Insights from a Real-World Scenario. The Oncologist. 19, 608–615 (2014).
4. Yardley, D. A. et al. nab-Paclitaxel Plus Carboplatin or Gemcitabine vs Gemcitabine Plus Carboplatin as First-Line Treatment for Patients with Triple-Negative Metastatic Breast Cancer: Results From the tnAcity Trial. Annals of Oncology. (2018).
5. Schmid, P. et al. Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer.New England Journal of Medicine. N Engl J Med. 379, 2108–2121 (2018).
Cited by
57 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献